The drug consists of fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered via an Ellipta dry powder inhaler.
Early child care attendance increased the risk for wheeze in children ≤2 years of age but decreased the risk for asthma in children 3 to 5 years of age.
In patients with COPD, transcatheter aortic valve replacement was associated with fewer respiratory-related complications than surgical aortic valve replacement.
Statins have anti-inflammatory and anti-oxidative effects, which could reduce exacerbations of both asthma and chronic obstructive pulmonary disease.
Triple therapy with fluticasone furoate, umeclidinium, and vilanterol was associated with a lower rate of exacerbations in chronic obstructive pulmonary disease.
A childhood measles infection may increase the risk for post-bronchodilator airflow obstruction in middle-age adults via its interaction with asthma and smoking.
A 55-year-old man with chronic obstructive pulmonary disease reports having some mild chest pain.
Preterm-born children had significantly more frequent preschool wheeze compared with children born at term.
No significant benefit of long-acting muscarinic antagonists over long-acting beta-agonists in reducing exacerbation risk in uncontrolled, persistent asthma
Adjunct long-acting muscarinic antagonist (LAMA) use with corticosteroids was associated with reduced exacerbation risk compared with placebo in patients with uncontrolled, persistent asthma. However, LAMA, long-acting beta-agonist (LABA), and inhaled corticosteroids (triple therapy) were not associated with lower risk for exacerbations compared with LABA and inhaled corticosteroids alone.
A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.
Treating chronic obstructive pulmonary disease remains challenging, particularly in terms of choosing the appropriate fixed-dose combination bronchodilator.
Greater Pi10 was associated with incident spirometry-defined chronic obstructive pulmonary disease in a general population-based sample without clinical lung disease.
Sputum viscoelastic properties were associated with lung function and disease status in patients with cystic fibrosis.
In patients with persistent asthma, single maintenance and reliever therapy was associated with a lower risk for exacerbations compared with inhaled corticosteroids as controller therapy and short-acting beta-agonists as relief therapy.
Tai chi found to be as effective as pulmonary rehabilitation for patients with chronic obstructive pulmonary disease.
It is still not known whether differences in mortality rates between patients who receive noninvasive vs invasive ventilation for acute exacerbations of COPD can be attributed to less severe disease or other factors.
Regardless of blood eosinophil count, omalizumab was an effective treatment in adult and pediatric patients with severe allergic asthma.
Researchers identified 6 distinct FEV1 lung function trajectories, 3 of which were responsible for 75% of the COPD burden.
Proteostasis Therapeutics is developing the combination treatment which includes a novel transmembrane conductance regulator (CFTR) amplifier (PTI-428), a third generation corrector (PTI-801) and a potentiator (PTI-808).
Findings for subsequent allergic disease following infant exposure in the first six months of life.